Please assess the completion status of the following clinical trial:

Trial Title: First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~General Inclusion Criteria:~1. Willing and able to provide informed consent;~2. 18 years of age and less than 75 years of age;~3. PE symptom duration ≤ 14 days;~4. Filling defect in at least one main or lobar pulmonary artery as determined by contrast enhanced chest CT;~5. RV/LV end diastolic diameter ratio ≥ 0.9 by CTA as determined by the investigative site;~6. Willing and able to comply with all study procedures and follow-up.~Exclusion Criteria:~1. Cerebrovascular Accident (CVA) or transient ischemic attack (TIA) within one (1) year;~2. Head trauma, or other active intracranial, or intraspinal disease within one (1) year;~3. Recent (within one month) or active bleeding from a major organ;~4. Intracranial condition(s) that may increase the risk of bleeding (e.g., neoplasms, arteriovenous malformations, or aneurysms);~5. Patients with bleeding diathesis;~6. Hematocrit \< 30%;~7. Platelets \< 100,000/μL;~8. INR \> 1.5;~9. aPTT \> 50 seconds in the absence of anticoagulants;~10. Major surgery within fourteen (14) days;~11. Serum creatinine \> 2 mg/dL;~12. Clinician deems high-risk for catastrophic bleeding;~13. History of heparin-induced thrombocytopenia (HIT);~14. Pregnancy;~15. Systolic blood pressure \< 90 mmHg for \> 15 minutes;~16. Any vasopressor support;~17. Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR);~18. Evidence of irreversible neurological compromise;~19. Life expectancy \< one (1) year;~20. Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to inclusion in the study;~21. Use of non-vitamin K oral anti-coagulants (NOACs), such as Rivaroxaban, Apixaban, Dabigatran, Edoxaban within 48 hours prior to inclusion in the study;~22. Use of enoxaparin sodium injection (Lovenox®) within 12 hours of procedure start time;~23. Profound bradycardia requiring a temporary pacemaker and/or inotropic support;~24. Previous enrollment in this study;~25. Morbidly obese (BMI \>45 kg/m2) patient who by the judgement of the investigator is high risk for bleeding;~26. Absolute contraindication to anticoagulation;~27. Uncontrolled hypertension;~28. Currently participating in another study;~29. In the opinion of the investigator, the subject is not a suitable candidate for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BEC Treatment (Type: EXPERIMENTAL): The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.

Based on this trial design, predict the completion outcome and termination type (if applicable).